The controversy behind goat’s blood for MS therapy

[MSUK]

It was 2007 when an article in the U.K. had taken Daval International Ltd. to task for not doing clinical trials on their drug, Aimspro. The article had brought up how, in seven years, only two very small trials had been done and of them, “one was inconclusive and the other was stopped early.”

Aimspro is only available in Britain under their “compassionate-use” regulations and that means, like CCSVI, patients have to use their own money to receive treatment. No health insurance companies (or state funded health regulators) will touch a non-FDA or non-MHRA approved therapy............. Read More - http://www.ms-uk.org/index.cfm/aimspro